LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Lantern Pharma Completes Targeted Enrollment For Lung Cancer Phase 2 Harmonic™ Clinical Trial In Japan For LP-300
Brief: Lantern Pharma Announces Appointment Of Dr. Lee Schalop To Board Of Directors
Brief: Lantern Pharma Reports Complete Response In Heavily Pre-Treated Lymphoma Patient In Phase 1 Clinical Trial
Brief: Lantern Pharma May Sell Shares for Up to $15.5 Million via Sales Agent
Brief: Lung Cancer Patient In Lantern Pharma’s Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years
Brief: Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference
Lantern Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Lantern Pharma Inc Qtrly EPS $-0.54
Lantern Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Lantern Pharma Inc expected to post a loss of 51 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-PSQ Holdings, Core Scientific, Keros
U.S. STOCKS ON THE MOVE-BlackRock, Terns Pharma, PSQ Holdings
U.S. STOCKS ON THE MOVE-Citi Trends, PG&E, BlackRock
Lantern Pharma rises on FDA 'fast track' tag for breast cancer drug
Brief: Lantern Pharma & Starlight Therapeutics Present LP-184